Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
β-Klotho deficiency protects against obesity through a crosstalk between liver, microbiota, and brown adipose tissue
Emmanuel Somm, Hugues Henry, Stephen J. Bruce, Sébastien Aeby, Marta Rosikiewicz, Gerasimos P. Sykiotis, Mohammed Asrih, François R. Jornayvaz, Pierre Damien Denechaud, Urs Albrecht, Moosa Mohammadi, Andrew Dwyer, James S. Acierno Jr., Kristina Schoonjans, Lluis Fajas, Gilbert Greub, Nelly Pitteloud
Emmanuel Somm, Hugues Henry, Stephen J. Bruce, Sébastien Aeby, Marta Rosikiewicz, Gerasimos P. Sykiotis, Mohammed Asrih, François R. Jornayvaz, Pierre Damien Denechaud, Urs Albrecht, Moosa Mohammadi, Andrew Dwyer, James S. Acierno Jr., Kristina Schoonjans, Lluis Fajas, Gilbert Greub, Nelly Pitteloud
View: Text | PDF
Research Article Endocrinology Metabolism

β-Klotho deficiency protects against obesity through a crosstalk between liver, microbiota, and brown adipose tissue

  • Text
  • PDF
Abstract

β-Klotho (encoded by Klb) is the obligate coreceptor mediating FGF21 and FGF15/19 signaling. Klb–/– mice are refractory to beneficial action of pharmacological FGF21 treatment including stimulation of glucose utilization and thermogenesis. Here, we investigated the energy homeostasis in Klb–/– mice on high-fat diet in order to better understand the consequences of abrogating both endogenous FGF15/19 and FGF21 signaling during caloric overload. Surprisingly, Klb–/– mice are resistant to diet-induced obesity (DIO) owing to enhanced energy expenditure and BAT activity. Klb–/– mice exhibited not only an increase but also a shift in bile acid (BA) composition featured by activation of the classical (neutral) BA synthesis pathway at the expense of the alternative (acidic) pathway. High hepatic production of cholic acid (CA) results in a large excess of microbiota-derived deoxycholic acid (DCA). DCA is specifically responsible for activating the TGR5 receptor that stimulates BAT thermogenic activity. In fact, combined gene deletion of Klb and Tgr5 or antibiotic treatment abrogating bacterial conversion of CA into DCA both abolish DIO resistance in Klb–/– mice. These results suggested that DIO resistance in Klb–/– mice is caused by high levels of DCA, signaling through the TGR5 receptor. These data also demonstrated that gut microbiota can regulate host thermogenesis via conversion of primary into secondary BA. Pharmacologic or nutritional approaches to selectively modulate BA composition may be a promising target for treating metabolic disorders.

Authors

Emmanuel Somm, Hugues Henry, Stephen J. Bruce, Sébastien Aeby, Marta Rosikiewicz, Gerasimos P. Sykiotis, Mohammed Asrih, François R. Jornayvaz, Pierre Damien Denechaud, Urs Albrecht, Moosa Mohammadi, Andrew Dwyer, James S. Acierno Jr., Kristina Schoonjans, Lluis Fajas, Gilbert Greub, Nelly Pitteloud

×

Figure 8

Antibiotic-mediated blockade of deoxycholic acid (DCA) production abrogates BAT activation and fatty liver protection in Klb–/– mice on high-fat diet (HFD).

Options: View larger image (or click on image) Download as PowerPoint
Antibiotic-mediated blockade of deoxycholic acid (DCA) production abroga...
(A) Brown adipose tissue (BAT) weight. (B) H&E staining of BAT sections. (C) O2 consumption (VO2) curves representing 2 consecutive days. Dark horizontal bars represent 12-hour dark phases. (D) Mean VO2 during light and dark phases. (E) Respiratory exchange ratio (RER = VCO2/VO2, where VCO2 is CO2 production) during light and dark phases. (F) BAT mRNA levels of thermogenic markers. (G) Liver weight. (H) H&E staining of liver sections. (I) Hepatic triglyceride content. (J) Hepatic mRNA levels of metabolic enzymes and transporters. (K) Hepatic mRNA levels of cholesterogenesis enzymes. (L) Hepatic mRNA levels of inflammatory markers. Results are expressed as mean ± SEM. n = 8 Klb–/– and n = 11 WT male mice on HFD+VCM per group. *P < 0.05 versus WT determined by unpaired t test. Scale bars: 100 μm (B and H). Individual values not represented (outside the range of the y axis): F (2.21 for Ucp3, 2.18 for Dio2, 1.78 for Elolv3, 1.70 and 2.14 for Pgc1a, and 1.61 for Nrip in WT group; 1.58 for Ucp3 and 1.57 for Elolv3 in Klb–/– group) and L (3.49 for Il6 in Klb–/– group).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts